期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

嵌合抗原受体修饰T细胞及其免疫治疗的研究进展 被引量：1

Introduction and Research Progress on Chimeric Antigen Receptor
下载PDF
导出
摘要 嵌合抗原受体T细胞免疫疗法(Chimeric Antigen Receptor T-Cell Immunotherapy,CAR-T)治疗肿瘤的方法是近年来发展发展最为迅速的一种肿瘤免疫新疗法。随着2017年Kymriah(Novartis)和Yescarta(Kite Pharma)两款药物被FDA批准上市,CAR-T细胞必将在肿瘤免疫治疗中发挥更重要的作用。CAR-T细胞疗法能克服局部免疫抑制,对肿瘤细胞的杀伤不受MHC(major histocompatibility complex)的限制等优势,但同时也必须面对在治疗过程中产生的细胞因子释放综合症(CRS)、脱靶效应和神经毒性等因素的困扰。因此在CAR-T细胞治疗的技术有效性和安全性还有待进一步研究。 Chimeric antigen receptor（CAR） T-cells therapy is an immunotherapy technology developed very rapidly in recent years. Kymriah（Novartis） and Yescarta（Kite Pharma） as the gene therpy approved by the FDA in 2017,CAR-T cells will play an important role in cancer immunotherapy in the future. CAR-T cells can overcome theimmunity suppression in the microenvironment of the tumor site,moreover,it is independent of major histocompatibility complex. Also there are many difficulties as Cytokine release syndrome, Neurological toxicity, On-target/off-tumor recognition in the tumor therapy. So its safety and effectiveness have yet to be studied.
作者 凤晓锋 Feng Xiao-feng(School of Life Sciences and Biotechnology,Shanghai20003)
机构地区 上海交通大学生命科学技术学院
出处 《生物化工》 2018年第1期99-101,共3页 Biological Chemical Engineering
关键词 CAR-T Kymriah Yescarta 细胞因子释放综合症 脱靶效应 CAR-T Kymriah Yescarta Cytokine release syndrome On- target/off-tumorrecognition
分类号 R730.51 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献51

  • 1Gross GT, Waks T, Eshhar Z. Expression of immunoglobulin-T- cell receptor chimeric molecules as functional receptors with antibody- type specificityU]. ProcNatlAcadSci U S A, 1989, 86(24):10024-10028.
  • 2Kershaw MH, Westwood JA, Parker LL, et al. A phase ][ study on adoptive immunotherapy using gene-modified T cells for ovarian cancer[J]. C/in Cancer Res, 2006, 12(20 Pt 1 ): 6106-6115.
  • 3Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells[J]. Blood, 2008, 112(6):2261-2271.
  • 4Louis CU, Straathof K, Bollard CM, et al. Enhancing the in vivo expansion of adoptively transferred EBV- specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients[J]. Blood, 2009, 113(11):2442-2250.
  • 5Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX : first clinical experienceD]. J ClinOncol, 2006, 24(13):e20-22.
  • 6Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survivalof transduced T lyrnphocytes and antiturnor activityU].J Immunol, 2009, 183(9):5563-5574.
  • 7Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor[J]. Nat Biotechnol, 2002, 20(1 ):70-75.
  • 8Chrnielewski M, Kopecky C, Hornnachaa, et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent rnacrophage response on tumor cells that have shut down tumor antigen expression[J]. Cancer Res, 2011, 71 (17):5697-5706.
  • 9Chmielewski M. Hornbach AA. AbkenH. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma[j]. Immunol Rev, 2014, 257(1 ):83-90.
  • 10Chmieleski M, Abken H. TRUCKs: the fourth generation of CARs[J]. Expert Opin Biol Ther, 201 5, 15(8):1145-1154.

共引文献5

同被引文献35

引证文献1

生物化工
2018年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部